Citation tools
"Measurable Residual Disease Assessment Using Next-Generation Flow in Patients With Relapsed and Refractory Multiple Myeloma Treated With a Combination of Carfilzomib, Lenalidomide, and Dexamethasone." Anticancer Research
43.1
(2023):
157-165.
Web. 29 Mar. 2024.